The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.

Holly LeeJason TayPeter DugganSylvia McCullochPaola NeriNizar J BahlisVictor H Jimenez-Zepeda

Published in: European journal of haematology (2020)

The management of AL amyloidosis and IDD must be individualized on the clinical characteristics, centers' access to care under the pandemic restrictions, and the epidemiological aspects of the outbreak.

Keyphrases

coronavirus disease
sars cov
healthcare
multiple myeloma
respiratory syndrome coronavirus
pain management
health insurance